






































New antiretroviral agent use affects prevalence of
HIV drug resistance in clinical care populations
Thibaut Davy-Mendeza,b, Joseph J. Erona,b, Laurence Bruneta,
Oksana Zakharovaa, Ann M. Dennisa and Sonia Napravnika,b
Objective: To estimate the prevalence of HIV drug resistance over time and identify risk 
factors for multiclass resistance.
Design: Prospective clinical cohort of HIV-infected patients at the University of North 
Carolina.
Methods: Among antiretroviral therapy (ART)-experienced patients in care 2000–
2016, we estimated annual prevalences of cumulative resistance, defined as at least 
one major mutation by drug class. Clinical data and multiple imputation were used 
when genotypic data were missing, and mutations were carried forward in time. We 
estimated resistance odds ratios comparing characteristics of patients in care in 2016.
Results: A total of 3682 patients contributed 23 169 person-years. Prevalence of at least 
one major resistance mutation, irrespective of viral suppression, peaked in 2005 with 
49% (95% confidence interval 46, 52) and decreased to 38% (35, 40) in 2016. 
Resistance to nucleoside reverse transcriptase inhibitors, protease inhibitors, and 
nonnucleoside reverse transcriptase inhibitors also peaked in 2005–2007 and 
decreased to 28 (26, 31), 14 (12, 16), and 27% (24, 29) in 2016, respectively. In 
2016, prevalence of integrase strand transfer inhibitor (INSTI) resistance was 2% (1, 3) 
and triple-class resistance 10% (9, 12). Over the study period, cumulative resistance 
was frequent among patients with detectable viremia, but uncommon among patients 
initiating ART post-2007. Among 1553 patients in care in 2016, ART initiation at an 
older age, with an INSTI, and with higher CD4þ cell counts were associated with 
resistance to fewer or no classes.
Conclusion: Prevalence of resistance to older ART classes has decreased in the last 10 
years in this clinical cohort, whereas INSTI resistance has increased but remained very 
low. Patients with viremia continue to have a high burden of resistance even if they 
initiated ART recently. 
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Introduction
Antiretroviral therapy (ART) reduces HIV morbidity and
mortality and prevents forward HIV transmission [1,2].
Poor ART adherence may lead to subtherapeutic drug
levels, incomplete suppression of viral replication, and
selection of resistance [3,4], which can limit the success of
subsequent therapy and result in further selection of
resistance [5]. Moreover, HIV strains with resistance-
conferring mutations can be transmitted to others [6].
Genotypic resistance testing, performed before initiating
treatment or after virologic failure, helps guide clinicians
in choosing an efficacious drug regimen [7]. In addition,
genotypic resistance testing of samples collected via
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population-based surveys provides drug resistance esti-
mates in regions where genotypes may not be available for
patient care [8–10].
Drug resistance prevalence is affected by changes in
treatment guidelines, including use of newer agents and
genotypic resistance testing, as well as patient turnover
due to care entry, loss to follow-up, or death. Capturing
complete resistance history, even in currently suppressed
patients, is essential to assess the burden of all resistance
with a potential clinical impact on patients, for example,
after regimen modification or simplification. However,
contemporary resistance prevalence is not well known,
because few observational studies have been conducted
since the introduction of newer boosted protease
inhibitors [11,12] and integrase strand transfer inhibitors
(INSTIs) [13–15], which have high barriers to resistance,
limiting the selection of resistance mutations at virologic
failure [11–13,16–19].
Characterizing resistance prevalence is also challenging
because resistance testing for individual patient care is not
consistently done in all viremic patients. Prevalence
estimates relying solely on available genotypes are
susceptible to changes in the use of resistance testing
and may exclude important groups of patients [20], and
they fail to capture archived variants harboring resistance
mutations [21–24]. In this study, we used clinical
information, available resistance tests, and multiple
imputation to estimate changes in resistance prevalence
between 2000 and 2016, and identify risk factors for
multiclass resistance in an HIV clinical cohort.
Methods
Study population
We included all ART-experienced patients in the
University of North Carolina (UNC) Center for AIDS
Research HIV Clinical Cohort (UCHCC) with at least
one HIV RNA viral load measurement after ART
initiation between 1 January 2000 and 31 December
2016, including patients who first entered HIV care prior
to 2000. The UCHCC is a prospective clinical cohort of
over 5000 HIV-infected adults followed at UNC
Hospitals after 1996 [25]. Laboratory testing is collected
electronically in real time. Diagnoses and medication
information are abstracted twice yearly from medical
records, and resistance mutations are abstracted from
genotype reports as they are performed. Prospective data
collection for the UCHCC and this secondary data
analysis have both been approved by the UNC
Institutional Review Board.
Measures
ART-experienced patients contributed data to a given
calendar year of analysis if they had at least one viral load
measurement in that year (defined as being in care), even
if they subsequently discontinued ART. Patients who
were out of care and had no viral load in a given calendar
year were excluded for that year but could contribute to
subsequent years. For each calendar year, patients were
considered viremic if they met any of the following: two
consecutive viral loads of more than 500 copies/ml at least
90 days post-ART initiation; one viral load of more than
500 and no evidence of care the following calendar year;
or a genotype test performed post-ART initiation. We
defined antiretroviral drug resistance by agent class as
having one or more major (bolded) mutation in the 2017
International Antiviral Society-USA list [26], including
genotypes performed both before and after ART
initiation. Genotypes performed prior to ART initiation
were available for 31% of patients in this study. The drug
classes examined were nucleoside reverse transcriptase
inhibitor (NRTI), non-NRTI (NNRTI), protease
inhibitor, and integrase strand transfer inhibitor (INSTI).
Resistance to entry and fusion inhibitors was not
considered in this study.
Analysis
For every calendar year from 2000 to 2016, we estimated
the prevalence of resistance among all patients receiving
care that year, as well as patients who were viremic that
year. Prevalence for each year was calculated by dividing
the total number of patients with resistance (both new and
prior resistance) by the number of eligible patients that
year. We also estimated resistance prevalence in the subset
of patients who initiated ART in 2007 or later. For each
group, we estimated resistance to at least one, two, three,
or four classes, and resistance to NRTIs, protease
inhibitors, NNRTIs, and INSTIs. INSTI and four-class
resistance were only estimated starting in 2007. Among
patients with triple-class resistance, we estimated the
annual proportion of patients with viremia.
Our algorithm for estimating resistance prevalence using
clinical information to impute missing genotypic
information was adapted from published work (Fig. 1)
[27]. Resistance mutations from genotype testing were
carried forward in time. Suppressed patients, including
those with no prior genotype test, were assumed to have
no new mutations. For patients with viremia in a given
year, resistance status for a drug class was considered
missing if no new genotype was obtained, resistance to
that class was not already known, and the patient was not
known to be off ART. Patients with missing resistance
status were assumed not to have any transmitted resistance
mutations to classes to which they had never been
exposed, with the exception of NNRTI. This decision
was based on research conducted in the UCHCC, in
which we estimated that, during most of the study period,
approximately 5–10% of newly infected patients each
year had transmitted resistance mutations to NNRTIs,
whereas estimates for protease inhibitors and NRTIs were
much lower [28]. Patients with missing resistance who
became suppressed without a change in ART regimen
were assumed to have no new mutations.
After applying these assumptions on the basis of available
clinical information, 10% of patient-years still had an
unknown resistance status for some of the drug classes,
and less than 1% of patient-years had an unknown
resistance status for all four classes. For the remaining
missing resistance, we conducted 50 multiple imputations
with the SAS procedure MI and the Markov Chain
Monte Carlo method with a single chain, assuming a
multivariate normal distribution [29]. Model estimates
and statistical tests from multiply imputed data sets were
combined using Rubin’s rules [30]. The variables used for
multiple imputation were calendar year, age at ART
initiation, sex, race, ethnicity, HIV risk factor, proximal
CD4þ cell count and viral load, number of drug
exposures in each class, and a history of ART initiation
with NRTIs only. Only viremic patient-years were
included in the multiple imputation model, as associations
between these characteristics and resistance can vary by
HIV RNA suppression [27]. Once resistance to a class was
imputed, it was considered present in all future years.
After imputing missing resistance status for all patient-
years, we estimated the prevalence of drug resistance for
each calendar year from 2000 to 2016, including both
new and prior resistance. We fit separate logistic
regression models with generalized estimating equations
to compare patient-years in different calendar periods
and to estimate time trends in each prevalence estimate,
using year as a linear predictor and including linear splines
with a knot when a peak was observed. For patients in
care in 2016, we used cumulative logistic regression (i.e.
ordinal logistic regression) with unequal slopes to model
the odds of having resistance to 0, at least 1, at least 2, or at
least 3 classes. We estimated unadjusted odds ratios (ORs)
and 95% confidence intervals (CIs) comparing patient
demographic and clinical characteristics. In a secondary
analysis, we estimated adjusted ORs with a multivariable
model including important characteristics selected a
priori. P values were two-sided and less than 0.05 was
considered statistically significant. All analyses were
conducted using SAS software, version 9.4 (SAS Institute,
Inc., Cary, North Carolina, USA).
Results
The study population comprised 3682 patients who
contributed 23 168 person-years in care after initiating
ART (Table 1). Overall, 30% of patient-years were
contributed by women, 42% by MSM, and 58% by
African-American patients. Half of patient-years were
contributed by patients who initiated ART prior to 1999
[interquartile range (IQR) 1996, 2005], and 34% by patients
whose first ART regimen contained only NRTI agents.
Compared with person-years in the 2000–2005 calendar
period, person-time in the 2012–2016 period was more
likely contributed by patients who were older [median age
48 (IQR 39, 55) vs. 42 (IQR 36, 48)], less likely to be
viremic (11 vs. 44%), having initiated ART more recently
[median year 2004 (IQR 1998, 2010) vs. 1997 (IQR 1995,
2000)], with higher CD4þ cell counts [median 286 (IQR
106, 443) vs. 237 (IQR 67, 404)] and less likely to have used
NRTI-only regimens (22 vs. 48%) (All P< 0.05).
Prevalence of resistance over time
Over the study period, the estimated prevalence of
resistance to NRTI and protease inhibitor drugs increased
Fig. 1. Algorithm to impute missing data on resistance mutations.
between 2000 and 2005 to a peak of 42 and 23% and
decreased to 28 and 14% in 2016, respectively (Fig. 2a, all
P< 0.05). Resistance to NNRTIs increased between
2000 and 2007 to a peak of 30% and decreased to 27% in
2016 (both P< 0.05). Prevalence of resistance to at least
one, two, and three classes of drugs all increased from
2000 to 2005 and decreased from 2005 to 2016 (Fig. 2b,
all P< 0.05 for both increase and decrease). Their peaks
in 2005 were 49, 32, and 14%, and they declined to 38,
22, and 10% in 2016, respectively. INSTI and four-class
resistance increased from 2007 to 2016 but remained low
with prevalences of 2 and 1% in 2016, respectively (both
P< 0.05). Eleven patients had observed mutations for
all four classes of drugs, cumulatively on all available
genotypes (Table, Supplemental Digital Content 1,
http://links.lww.com/QAD/B349). Their most com-
mon mutations were M184V (10 patients) for NRTI,
M46I (six patients) for protease inhibitor, K103N (eight
patients) for NNRTI, and Q148H (five patients) for
INSTI. Almost two-thirds of these patients initiated ART
either with only NRTIs (45%) or an unboosted protease
inhibitor (18%), and the median CD4þ cell count of these
11 patients was 53 (IQR 9, 330) at ART initiation.
The proportion of patients in care who had detectable
viremia in a given year decreased over the study period
from 44% in 2000 to 10% in 2016 (not shown, P< 0.05).
Among patients who had viremia during a given calendar
year, resistance to NNRTIs and INSTIs increased over
the study period (Fig. 2c, both P< 0.05), whereas
resistance to NRTIs and protease inhibitor did not change
significantly (P¼ 0.18 and 0.07, respectively). In 2016,
resistance prevalence was 52% for NRTI, 57% for
NNRTI, 26% for protease inhibitor, and 11% for INSTI
agents. Resistance to at least one drug class remained
above 50% throughout the period with no evidence of
change (P¼ 0.87), reaching 69% in 2016 (Fig. 2d). Two-
class resistance did not change over time either (P¼ 0.25),
whereas three-class and four-class resistance increased
(both P< 0.05). These were estimated to be 46, 26, and
5% in 2016, respectively.
In patients who initiated ART in 2007 or later, regardless
of viremia, the prevalence of resistance to each class
remained low between 2007 and 2016 and was estimated
to be 8% for NRTI, 3% for protease inhibitor, 16% for
NNRTI, 1% for INSTI drugs in 2016 (Fig. 2e). Only
INSTI resistance increased between 2007 and 2016
(P< 0.05). One-class resistance prevalence was 20% in
2016, whereas multiclass resistance was uncommon, with
6% for two, 2% for three, and less than 1% for four classes,
and these did not change significantly over time (Fig. 2f).
However, among patients initiating ART since 2007 with
viremia in a given year, one-class resistance prevalence










Sexual risk group, N (%)
Heterosexual male 6497 (28%) 2278 (32%) 2298 (28%) 1921 (24%)
Female 6837 (30%) 2171 (31%) 2400 (29%) 2266 (28%)
MSM 9835 (42%) 2571 (37%) 3474 (43%) 3790 (48%)
IDUa, N (%) 2849 (12%) 1118 (16%) 1008 (12%) 723 (9%)
Race/ethnicity, N (%)
White 7601 (33%) 2336 (33%) 2667 (33%) 2598 (33%)
African-American 13 504 (58%) 4143 (59%) 4707 (58%) 4654 (58%)
Hispanic or other 2064 (9%) 541 (7%) 798 (10%) 725 (9%)
Initial ART regimen
NRTI only 7761 (34%) 3396 (48%) 2572 (31%) 1793 (22%)
Ritonavir-boosted PI 3100 (13%) 411 (6%) 1355 (17%) 1334 (17%)
Unboosted PI 3488 (15%) 1498 (21%) 1190 (15%) 802 (10%)
NNRTI 6173 (27%) 1237 (18%) 2314 (28%) 2622 (33%)
INSTI 902 (4%) 0 (0%) 111 (1%) 791 (10%)
Otherb 1745 (8%) 478 (7%) 630 (8%) 637 (8%)
Year of ART start, median (IQR) 1999 (1996, 2005) 1997 (1995, 2000) 2000 (1996, 2005) 2004 (1998, 2010)
Age at ART start, median years (IQR) 36 (29, 44) 36 (30, 43) 36 (30, 44) 36 (29, 44)
CD4þ at ART startc, median cells/ml (IQR) 253 (78, 416) 237 (67, 404) 240 (68, 403) 286 (106, 443)
Current HIV viremiad, N (%) 5694 (25%) 3055 (44%) 1797 (22%) 842 (11%)
Current CD4þ cell counte, median cells/ml (IQR) 504 (301, 729) 401 (211, 628) 496 (304, 714) 596 (395, 807)
Current age, median years (IQR) 45 (37, 52) 42 (36, 48) 46 (38, 52) 48 (39, 55)
ART, antiretroviral therapy; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase
inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
aIDU identified as a risk factor for HIV acquisition.
bIncludes NRTI-sparing regimens (244 person-years), regimens containing more than two classes of agents (724 person-years), regimens containing
only an anchor agent (165 person-years), and unknown regimens (612).
cMissing for 5422 (23%) person-years.
dDefined as two HIV RNA more than 500 copies/ml post-ART initiation, or one RNA more than 500 copies/ml post-ART initiation with no care in
the subsequent calendar year, or having a genotype test performed post-ART initiation.
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2 classes (P for increase/decrease both <0.05)
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Number in care 
1151 1161 1174 1231 1335 1446 1574 1634 1553 
Number in care 
1151 1161 1174 1231 1335 1446 1574 1634 1553 
Number with HIV viremia 
510 552 502 427 299 209 180 172 155 
Number with HIV viremia 
510 552 502 427 299 209 180 172 155 
Number in care who initiated ART post-2007 
69 176 268 374 475 573 640 687 697 681 
Number in care who initiated ART post-2007 




Fig. 2. Estimated prevalence of resistance mutations and 95% confidence bands by drug class and multiclass combinations.
Among all antiretroviral therapy-experienced patients in care, 2000–2016 (panels a and b); among antiretroviral therapy-
experienced patients in care with HIV viremia, 2000–2016 (panels c and d); among patients in care who initiated antiretroviral
therapy in 2007 or later, 2007–2016 (panels e and f).
was 53% (95% CI 40, 66) in 2016 with no detected
change over time (Figure, Supplemental Digital Content
2, http://links.lww.com/QAD/B349, P¼ 0.83). INSTI
resistance prevalence increased to 7% (95% CI 0, 14) in
2016 (P< 0.05), but resistance to other classes or several
classes did not appear to change. However, the number of
patients in this subgroup was small, and our prevalence
estimates were imprecise.
Among patients estimated to have triple-class resistance,
the proportion with HIV viremia each year decreased
over the study period (Fig. 3, P< 0.05). In 2000, 94% of
84 patients with triple-class resistance had viremia,
compared with 67% of 172 patients in 2005, 37% of
170 patients in 2010, and 25% of 163 patients in 2016.
Risk factors for resistance in 2016
In 2016, 1553 ART-experienced patients were in care,
and 155 (10%) of them were viremic (Table 2). One-third
of these patients initiated ART prior to 2000, and 14, 15,
and 30% with an INSTI-based, boosted protease
inhibitor (bPI)-based, or NNRTI-based regimen,
respectively. Thirty percent had been exposed to over
eight ART agents. In separate models for each charac-
teristic, examining odds of no resistance, single, dual, and
triple class resistance, race/ethnicity, female sex, and IDU
were not associated with having any major resistance,
whereas being MSM, older age at ART initiation, and
higher nadir CD4þ cell counts were associated with no or
lower levels of resistance (Table 2). Patients who had
detectable viremia in 2016 had 3.58 times (95% CI 2.43,
5.27) the odds of two-class resistance, compared with
suppressed patients. Compared with patients who had
initiated ART with an NNRTI-based regimen, patients
who had initiated with an INSTI had lower odds of
resistance (OR 0.25 for two classes; 95% CI 0.10, 0.59),
whereas those who had initiated with unboosted protease
inhibitors, NRTI only and other regimens had greater
odds of resistance. Exposure to more than eight drugs
substantially increased the likelihood of resistance with an
OR of two-class resistance of 16.15 (95% CI 11.74,
22.22). In a secondary analysis, in a multivariable model
including race/ethnicity, sexual risk group, IDU, detect-
able HIV viral load, nadir CD4þ cell count, age at ART
initiation, and first ART regimen, most associations were
unchanged with the exception of MSM status and INSTI
and bPI regimens which were similar to unadjusted
estimates but less precise and no longer statistically
significant (Table, Supplemental Digital Content 3,
http://links.lww.com/QAD/B349).
Discussion
In this study, the prevalence of resistance to NRTI,
NNRTI, and protease inhibitor agents increased from
2000 to 2005–2007 and subsequently decreased through
2016. The proportion of patients with HIV viremia
decreased over time, although those with viremia had a
consistently high prevalence of resistance including
multiclass resistance. Resistance to INSTI drugs and
four-class resistance were consistently low, although slight
increases were observed since 2007. Most patients
initiating ART in more recent years remained virologi-
cally suppressed; however, the patients with detectable

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































virus experienced a high burden of resistance to at least
one class, especially NNRTIs and NRTIs.
Decreases in resistance beginning in the mid-2000s can be
attributed to several changes in ARTregimens used in that
period. Atazanavir and darunavir, approved in 2003 and
2006, respectively, have high barriers to resistance,
are effective against virus resistant to earlier protease
inhibitors, and can be given once daily, facilitating
adherence [12,17,31–33]. In addition, efavirenz became
available in a single-tablet regimen in 2006, and etravirine,
active against virus resistant to earlier NNRTIs, was
approved in 2008 [34,35]. Boosted protease inhibitors
and efavirenz were frequently prescribed as first-line
therapy in our cohort through the early 2010s [36], likely
resulting in the high rates of virologic suppression and
lower resistance acquisition we observed. In addition, the
introduction of these agents, as well as INSTIs [34,37],
allowed patients harboring resistant HIV variants to
achieve and maintain virologic suppression, limiting
acquisition of additional resistance mutations.
NNRTI resistance persisted through the end of the study
period, as did resistance among patients with viremia.
This persistence is likely linked to patients experiencing
virologic failure on NNRTI-based regimens, which have
low barriers to resistance with emerging variants
frequently having both NNRTI and NRTI resistance
[38,39]. Transmitted resistance to NNRTIs was observed
in 5–10% of patients in our cohort annually in the 2000s
and may have contributed as well [28]. In addition, there
was a large uptake of raltegravir and elvitegravir in our
cohort [36]. Although these potent drugs lead to high
rates of viral suppression [14,15,36], 20–50% of virologic
failures on these agents in clinical trials have emergence of
resistance, frequently including both INSTI and NRTI
mutations [40,41]. If similar resistance emergence
occurred in our patients, this may have contributed to
the unchanging resistance prevalence in viremic patients,
as well as to the small increase in INSTI resistance
between 2007 and 2016 in our entire cohort.
Dolutegravir has a higher barrier to resistance than first-
generation INSTIs, with no emergence of resistance to
INSTI or NRTI in first-line studies and rare case reports
in clinical practice [13,17,18,42]. The recently approved
INSTI bictegravir may have a similar barrier to resistance
[43–45]. Uptake of these agents in clinical practice,
especially in new single-tablet formulations, will likely
limit emergence of variants with INSTI and NRTI
resistance and help maintain INSTI prevalence at the low
levels observed in this study. Notably, transmitted
resistance to INSTIs remains very rare in North Carolina
[46] and is unlikely to contribute substantially to increases
in overall INSTI resistance.
Studies limited to clinical specimens of patients with
virologic failure have reported high prevalence of
resistance to NRTI, protease inhibitor, and NNRTI
drugs and multiclass combinations, as we found in our
cohort among patients with detectable viremia [47–50].
In addition, a North Carolina study of available genotypes
reported a 7% INSTI resistance prevalence for viremic
individuals assumed to be treatment-experienced, similar
to the estimate in viremic patients in 2016 in our study
[46]. A large study of North American cohorts (including
UCHCC data), which first developed the imputation
algorithm adapted in our study, also found an increasing
trend in resistance prevalence for the period 2000–2005
among all patients, regardless of viremia [27]. However,
their estimates were lower than the ones presented here,
likely because they defined resistance as intermediate level
or above per the Stanford algorithm rather than a single
major mutation [51]. In a large Swiss cohort, using
different imputation methods to estimate resistance,
investigators reported a similar decrease in overall and
triple-class resistance, and lower resistance prevalences for
patients who have initiated ART more recently [52,53].
Our cohort previously reported that exposure to more
ART drugs and ART initiation with unboosted protease
inhibitors were strong predictors of triple-class resistance
[54]. In this study, we found that patients who had been
exposed to fewer drugs and initiated ART in recent years
with potent INSTI-based regimens had lower odds of
prevalent resistance. MSM status and older age at ART
initiation were also associated with lower odds of
resistance, consistent with studies showing lower risk
of acquiring mutations for these patients [55–58]. These
associations likely reflect patient characteristics linked to
better treatment adherence [33,59,60] and therefore
virologic suppression. In addition, we found an associa-
tion between high nadir CD4
þ cell counts and lower
resistance, which may be explained by patients in more
recent years entering care earlier with higher CD4þ cell
counts and lower viral loads, as well as by a possible lower
incidence of drug toxicity when initiating ARTwith high
CD4þ counts that may lead to better adherence and fewer
treatment interruptions [61]. Higher nadir CD4þ may
also reflect health-seeking behavior leading to earlier HIV
testing and care and to better treatment adherence
[33,59,60,62–64].
To our knowledge, this is the first US study to examine
the prevalence of drug resistance in an entire clinical
cohort since the uptake of INSTI agents. Our approach
builds on a previously developed algorithm used to
address missing genotypes and extends prior studies by
including more recent observation time and new agents.
This study benefits from granular longitudinal data used
to impute missing resistance and represent what clinicians
might see in their patient populations over time, although
this imputation relied on strong clinical and statistical
assumptions. In contrast, studies with only one genotype
available per patient are likely to miss archived mutations
and underestimate the burden of potentially clinical
relevant resistance, and studies restricted to viremic
patients can overestimate true prevalence [20]. Capturing
previously acquired resistance is especially important in
populations in which patients have had many ART
exposures, as past mutations can resurface and impact
treatment decisions such as regimen changes or simpli-
fications to fewer than three drugs.
One limitation of this study is that our estimates could
be underestimating resistance prevalence if mutations
occurred prior to the introduction of genotype testing or
prior to entering care at UNC. Second, this study used
data from a single clinical site in the Southeastern United
States and may not be representative of other geographical
settings. Future studies will need to confirm the trends we
observed in other patient populations as well as determine
whether the increasing uptake of second-generation
INSTIs has the expected impact on drug resistance
prevalence.
In the UCHCC, HIV drug resistance has become less
prevalent, and INSTI resistance remains rare. Patients
who initiated ART in the last decade have consistently
low resistance prevalence estimates, and patients who
have accumulated triple-class resistance are increasingly
able to achieve virologic suppression. Among patients
currently in care, those who have initiated ART in recent
years with potent regimens, have been exposed to fewer
agents and were not as immunosuppressed at initiation are
less likely to harbor highly resistant virus. These trends are
likely to persist with continued uptake of potent drugs
with high resistance barriers. Meanwhile, nonadherent
patients failing therapy may continue to develop
resistance in spite of novel regimens. Continuing to
monitor HIV drug resistance in the clinical setting is
important to identify trends and factors that can limit
effective treatment options and can reduce the impact of
ART on patient and community health.
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